Open Access Full Text Article

## CORRIGENDUM

## Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]

Barabássy Á, Sebe B, Acsai K, et al. *Neuropsychiatr Dis Treat*. 2021;17:957–970.

read "2 (0.3)". Total 1.5-6 mg/d column, "0" should read "3 (0.1)".

The authors have advised that there are errors in the first row of Table 5 on page 963.

Cariprazine 4.5 mg column, the value "1 (0.0)" should read "1 (0.2)". Cariprazine 6 mg column, "2 (0.0)" should

The authors apologize for these errors.

## Neuropsychiatric Disease and Treatment

## **Dove**press

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peerreviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the 'PsycINFO' database and CAS, and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimo-nials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal

https://doi.org/10.2147/NDT.S316858

Neuropsychiatric Disease and Treatment 2021:17 1481

1481

© 2021 Barabássy et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/ the work you hereby accept the Terms.Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. for permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).